RB To Split OTC And Infant Nutrition As CEO Hits Reset Button
Executive Summary
Reckitt Benckiser's new CEO Laxman Narasimhan has unveiled a turnaround plan which will see the company's OTC drugs and dietary supplements housed in a separate business to its infant nutrition products. RB is investing £2bn to get back on track after a couple of difficult years.
You may also be interested in...
Reckitt Seeking Continuity With Promotion Of Health Boss Licht To CEO
Reckitt's next CEO will be Health business president Kris Licht. Following an eight month-long search, the company selected Licht after he impressed with a successful turnaround of Reckitt's consumer health operation.
Reckitt's CEO Unexpectedly Quits After Three Years At The Helm
Reckitt's CEO Laxman Narasimhan will leave the company at the end of September motivated by a desire to return to the US. Company director Nicandro Durante will take the reins on an interim basis while the UK-based health and hygiene giant seeks a long-term replacement.
Reckitt Restructure Seeks To Maximize Dietary Supplement Growth
Reckitt has identified “lots of growth spaces and lots of growth potential” for its vitamins, minerals and supplements business, which it will seek to capitalize on by moving the operation to its OTC-focused Health unit.